The detection of NK cell alloreactivity by flow cytometric CD107a assay

Dianne De Santis; Bree Foley; Campbell S Witt; Frank T Christiansen

doi:10.1007/978-1-61779-842-9_27

The detection of NK cell alloreactivity by flow cytometric CD107a assay

Dianne De Santis
, Bree Foley
, Campbell S Witt
, Frank T Christiansen

Paediatrics

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Natural killer (NK) cell alloreactivity can be exploited in haploidentical (one haplotype mismatched) haematopoietic stem cell transplantation (HSCT) to prevent leukaemia relapse, rejection, and graft-vs-host disease (GVHD) (Blood 94:333-339; Science 295:2097-2100). If NK cell alloreactivity is to be exploited in HSCT, it is important to be able to reliably select donors who have NK alloreactivity towards the patient. The detection of donor NK alloreactivity towards patient target cells has traditionally been evaluated by NK cell cloning and (51)Cr-release cytotoxicity assay. This approach is complex and time consuming with results taking up to 6 weeks. Here, we detail a novel flow cytometric CD107a-based assay capable of detecting NK cell alloreactivity in 14 days.

Original language	English
Pages (from-to)	477-89
Number of pages	13
Journal	Methods in molecular biology (Clifton, N.J.)
Volume	882
DOIs	https://doi.org/10.1007/978-1-61779-842-9_27
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/978-1-61779-842-9_27

Cite this

@article{8aeed230fc8f48c8907519fae7566f72,

title = "The detection of NK cell alloreactivity by flow cytometric CD107a assay",

abstract = "Natural killer (NK) cell alloreactivity can be exploited in haploidentical (one haplotype mismatched) haematopoietic stem cell transplantation (HSCT) to prevent leukaemia relapse, rejection, and graft-vs-host disease (GVHD) (Blood 94:333-339; Science 295:2097-2100). If NK cell alloreactivity is to be exploited in HSCT, it is important to be able to reliably select donors who have NK alloreactivity towards the patient. The detection of donor NK alloreactivity towards patient target cells has traditionally been evaluated by NK cell cloning and (51)Cr-release cytotoxicity assay. This approach is complex and time consuming with results taking up to 6 weeks. Here, we detail a novel flow cytometric CD107a-based assay capable of detecting NK cell alloreactivity in 14 days.",

keywords = "Flow Cytometry, Hematopoietic Stem Cell Transplantation, Humans, Killer Cells, Natural/cytology, Lysosomal-Associated Membrane Protein 1/immunology, Transplantation, Homologous",

author = "\{De Santis\}, Dianne and Bree Foley and Witt, \{Campbell S\} and Christiansen, \{Frank T\}",

year = "2012",

doi = "10.1007/978-1-61779-842-9\_27",

language = "English",

volume = "882",

pages = "477--89",

journal = "Methods in molecular biology (Clifton, N.J.)",

issn = "1064-3745",

publisher = "Humana Press Inc.",

}

TY - JOUR

T1 - The detection of NK cell alloreactivity by flow cytometric CD107a assay

AU - De Santis, Dianne

AU - Foley, Bree

AU - Witt, Campbell S

AU - Christiansen, Frank T

PY - 2012

Y1 - 2012

N2 - Natural killer (NK) cell alloreactivity can be exploited in haploidentical (one haplotype mismatched) haematopoietic stem cell transplantation (HSCT) to prevent leukaemia relapse, rejection, and graft-vs-host disease (GVHD) (Blood 94:333-339; Science 295:2097-2100). If NK cell alloreactivity is to be exploited in HSCT, it is important to be able to reliably select donors who have NK alloreactivity towards the patient. The detection of donor NK alloreactivity towards patient target cells has traditionally been evaluated by NK cell cloning and (51)Cr-release cytotoxicity assay. This approach is complex and time consuming with results taking up to 6 weeks. Here, we detail a novel flow cytometric CD107a-based assay capable of detecting NK cell alloreactivity in 14 days.

AB - Natural killer (NK) cell alloreactivity can be exploited in haploidentical (one haplotype mismatched) haematopoietic stem cell transplantation (HSCT) to prevent leukaemia relapse, rejection, and graft-vs-host disease (GVHD) (Blood 94:333-339; Science 295:2097-2100). If NK cell alloreactivity is to be exploited in HSCT, it is important to be able to reliably select donors who have NK alloreactivity towards the patient. The detection of donor NK alloreactivity towards patient target cells has traditionally been evaluated by NK cell cloning and (51)Cr-release cytotoxicity assay. This approach is complex and time consuming with results taking up to 6 weeks. Here, we detail a novel flow cytometric CD107a-based assay capable of detecting NK cell alloreactivity in 14 days.

KW - Flow Cytometry

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Killer Cells, Natural/cytology

KW - Lysosomal-Associated Membrane Protein 1/immunology

KW - Transplantation, Homologous

UR - https://www.scopus.com/pages/publications/84867373360

U2 - 10.1007/978-1-61779-842-9_27

DO - 10.1007/978-1-61779-842-9_27

M3 - Article

C2 - 22665251

SN - 1064-3745

VL - 882

SP - 477

EP - 489

JO - Methods in molecular biology (Clifton, N.J.)

JF - Methods in molecular biology (Clifton, N.J.)

ER -

The detection of NK cell alloreactivity by flow cytometric CD107a assay

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this